Hyperosmolar therapy for raised intracranial pressure. by Benardete, Ethan A
Thomas Jefferson University
Jefferson Digital Commons
Department of Neurosurgery Faculty Papers Department of Neurosurgery
12-27-2012
Hyperosmolar therapy for raised intracranial
pressure.
Ethan A Benardete
Thomas Jefferson University, Ethan.Benardete@jefferson.edu
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/neurosurgeryfp
Part of the Neurology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Neurosurgery Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Benardete, Ethan A, "Hyperosmolar therapy for raised intracranial pressure." (2012). Department of
Neurosurgery Faculty Papers. Paper 22.
http://jdc.jefferson.edu/neurosurgeryfp/22
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;26 nejm.org december 27, 20122554
durable control of recurrent respiratory papillo-
matosis.4,5 Whether these pathways were also 
disrupted in the lung tumors of the patient de-
scribed by Yuan and colleagues was not reported. 
Yuan et al. describe a cell-culture technique that 
was used to identify specific treatment for recur-
rent respiratory papillomatosis, but other agents 
may also be effective, and caution is advised be-
fore broadly using histone deacetylase inhibitors 
for recurrent respiratory papillomatosis.
Raj K. Batra, M.D. 
Guy W. Soo Hoo, M.D., M.P.H.
Veterans Affairs Greater Los Angeles Healthcare System 
Los Angeles, CA 
guy.soohoo@va.gov
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The Authors Reply: Batra and Soo Hoo support 
our personalized cell technique that helped us to 
identify a therapy for progressive recurrent respi-
ratory papillomatosis. Although we found that 
vorinostat was cytocidal in vitro and clinically ef-
fective in vivo, we agree with their comment that 
there may be additional therapeutic agents that 
our approach might be able to validate. Indeed, 
we are currently expanding our studies to explore 
such possibilities as well as applying our approach 
to nonviral neoplasia. However, we do not agree 
with their postulate that a “hit-and-run” mecha-
nism was operative in the patient we described. 
Our polymerase-chain-reaction (PCR), reverse-
transcriptase PCR, and cloning experiments in-
dicate that wild-type and mutant HPV type 11 
genomes were present in the laryngeal tumor 
and lung tumor, respectively. These findings are 
consistent with the well-documented role of HPV 
in virtually all cases of recurrent respiratory papil-
lomatosis.1-3
Hang Yuan, Ph.D. 
Xuefeng Liu, M.D. 
Richard Schlegel, M.D., Ph.D.
Georgetown University Medical Center 
Washington, DC 
schleger@georgetown.edu
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Hyperosmolar Therapy for Raised Intracranial Pressure
To the Editor: Ropper (Aug. 23 issue)1 recom-
mends the use of mannitol at intervals of 2 to 4 or 
more hours to reduce intracranial pressure. Man-
nitol has been used for four decades to reduce 
intracranial pressure without solid evidence of 
benefit. In a randomized, controlled trial involv-
ing patients with intracerebral hemorrhage, man-
nitol improved neither the mortality nor the 
outcomes at 3 months.2 Mannitol also did not 
improve cerebral blood flow as compared with 
saline in patients with intracerebral hemorrhage.3 
In a study involving 6 patients with large hemi-
spheric infarctions, mannitol boluses were asso-
ciated with a clinically significant reduction of 
brain volume, which was most marked in the 
normal hemisphere.4 In another blinded study, 
mannitol administered in a 20% solution in bo-
luses of 1.5 g per kilogram of body weight resulted 
in clinical improvement for 30 to 60 minutes in 
5 of 12 patients with intracerebral hemorrhage, 
without a significant change in horizontal or ver-
tical shift on magnetic resonance imaging.5 Fre-
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quent and large doses of mannitol result in for-
mation of idiogenic osmoles, leading to a reduction 
in efficacy and even to rebound brain edema. We 
therefore think that mannitol should be used 
cautiously in patients with raised intracranial 
pressure.
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Jayantee Kalita, M.D., D.M. 
Gourav Goyal, M.D., D.M.
Sanjay Gandhi Postgraduate Institute of Medical Sciences 
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To the Editor: Hypertonic saline has been as-
sociated with clinically significant renal insuffi-
ciency or acute renal failure in pediatric patients 
being treated for intracranial hypertension. In one 
study, 2 of 10 children being treated with man-
nitol and hypertonic saline for intracranial hyper-
tension after traumatic brain injury required he-
modialysis for renal failure.1 In our study, we 
observed an increase in the serum creatinine 
level that was two to three times as high as the 
baseline level; this increase correlated with an in-
crease in the serum sodium level above 160 mmol 
per liter (serum osmolarity, >320 mOsm per liter) 
with the use of hypertonic saline (without man-
nitol) in pediatric patients with intracranial hy-
pertension and maintenance of a euvolemic hyper-
osmolar state.2 As a result, our pediatric intensive 
care practitioners will attempt to avoid increas-
ing the serum sodium level above 160 mmol per 
liter (serum osmolarity, >320 mOsm per liter) 
when administering hypertonic saline for treating 
intracranial hypertension in pediatric patients.
Jimmy W. Huh, M.D. 
Margaret A. Priestley, M.D.
University of Pennsylvania Perelman School of Medicine 
Philadelphia, PA
Troy E. Dominguez, M.D.
Great Ormond Street Hospital 
London, United Kingdom
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To the Editor: Ropper does not mention hypo-
natremic encephalopathy as a cause of raised in-
tracranial pressure.1 An equation for estimating 
the amount of hypertonic saline necessary to in-
crease the serum sodium level is provided, and it 
is recommended that biochemical measurements 
(levels of serum sodium or serum osmolarity, 
blood urea nitrogen, and serum creatinine) be 
checked every 8 hours. It is not mentioned that 
conditions associated with raised intracranial 
pressure are frequently associated with the syn-
drome of inappropriate antidiuretic hormone se-
cretion (SIADH) and cerebral salt wasting.2 Pa-
tients with SIADH and cerebral salt wasting can 
have hypertonic urine, with a combined urinary 
sodium and potassium concentration greater than 
that of plasma. The use of normal saline could 
actually result in a decrease in the serum sodium 
level, and the use of 3% saline could fail to raise 
the serum sodium level as much as calculated.3 
A continuous infusion of both normal saline and 
3% saline will probably be required to maintain 
hyperosmolality, and the serum sodium level 
should be checked at least every 4 hours.2 A new 
class of drugs, vasopressin antagonists, may have 
a role in achieving and maintaining hyperosmolal-
ity in patients with raised intracranial pressure.4
Michael L. Moritz, M.D.
Children’s Hospital of Pittsburgh 
Pittsburgh, PA 
michael.moritz@chp.edu
Juan C. Ayus, M.D.
Renal Consultants of Houston 
Houston, TX
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To the Editor: Important details regarding man-
nitol were omitted from Ropper’s article regard-
ing management of elevated intracranial pres-
sure. Ropper asserts that mannitol causes an 
osmotic diuresis, therefore increasing the serum 
sodium concentration, which leads to water 
shifting out of the brain due to an osmotic gradi-
ent. The article suggests that kidney function is 
necessary for mannitol to reduce intracranial 
pressure. However, in our practice, my colleagues 
and I have used mannitol (0.25 to 1.0 g per kilo-
gram of body weight intravenously) to control 
intracranial pressure in patients with anuric re-
nal failure who are receiving long-term intermit-
tent hemodialysis. In this clinical situation, we 
have observed rapid, sustained decreases in intra-
cranial pressure with the administration of man-
nitol. It is likely that the action of mannitol is due 
to increased plasma osmolarity after administra-
tion, causing water to shift out of the brain (for 
which renal function is not required).1 Other 
possible mechanisms for the reduction of intra-
cranial pressure associated with mannitol include 
an increase in cerebral perfusion,2 causing cere-
bral vasoconstriction,3 and decreased production 
of cerebrospinal f luid.4 Other physicians may 
find, as we have, that the use of mannitol even in 
patients with chronic renal failure and elevated 
intracranial pressure is beneficial.
Ethan A. Benardete, M.D., Ph.D.
Thomas Jefferson University 
Philadelphia, PA 
ethan.benardete@jefferson.edu
No potential conflict of interest relevant to this letter was re-
ported.
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The Author Replies: Misra and colleagues es-
chew the use of mannitol for raised intracranial 
pressure. This view may have merit, but they cite 
their own randomized trial1 that involved approx-
imately 60 patients, a third of whom had a cere-
bral hemorrhage smaller than 20 ml in volume 
and a third of whom had a cerebral hemorrhage 
larger than 40 ml in volume. As I discuss in my 
editorial2 on the article by Chesnut et al.3 in this 
issue of the Journal, patients with small masses 
may not need treatment for intracranial pressure 
at all, and there may be a limited benefit to treat-
ing those with large lesions, so I am uncertain 
whether Misra’s study settles the question of the 
usefulness of mannitol. If Misra and colleagues 
are questioning entirely the need to reduce intra-
cranial pressure in cerebral hemorrhage, that is 
an interesting but separate polemic.
The risks of excessive dehydration in children 
are well noted by Huh and colleagues, and I com-
mented in my article that serum sodium levels 
over 160 mmol per liter, arbitrarily stated by others 
to be the upper limit for safety, have been safely 
exceeded in adults.
Hyponatremic encephalopathy is an interest-
ing entity, but in my experience it has not been 
obligatorily tied to brain swelling, especially 
when the cause is the natriuretic Nelson’s syn-
drome. The other points made by Moritz and 
Ayus are worth noting, and vasopressin antago-
nists that cause hyperosmolarity are a new pros-
pect as treatment for raised intracranial pres-
sure. An additional issue regarding the correction 
of hyponatremia is the risk of “osmotic demye-
lination” (formerly called “central pontine mye-
linolysis”) if the level of sodium is made to rise 
too rapidly.
In response to the point made by Benardete 
about mannitol being effective even in patients 
with renal failure: my article indicates that a 
“sustained” reduction of intracranial pressure re-
quires osmotic diuresis. I accept that the contin-
ued circulation of mannitol in patients with renal 
failure might allow a prolonged hyperosmolar 
effect until the sugar is metabolized, but repeat 
dosing would be required to sustain hyperosmo-
larity, and chronic renal failure of a degree that 
prevents an osmotic diuresis is not typical in 
circumstances of raised intracranial pressure. 
Benardete is probably aware that the other often-
cited effects of mannitol on intracranial pres-
The New England Journal of Medicine 
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on August 10, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
correspondence
n engl j med 367;26 nejm.org december 27, 2012 2557
sure have been minor or transient in clinical 
studies.
Allan H. Ropper, M.D.
Brigham and Women’s Hospital 
Boston, MA
Since publication of his article, the author reports no further 
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Missing Data in Clinical Trials
To the Editor: Little et al. (Oct. 4 issue)1 men-
tion limiting “the burden and inconvenience of 
data collection on the participants” as one of sev-
eral ideas for limiting missing data in the con-
duct of clinical trials. Actually, this idea should 
be a design feature, and it is also important in 
limiting the burden on the investigator (a critical 
factor in successful data retrieval as well as pa-
tient accrual). Prominent trialists have long cham-
pioned simple randomized trials for these and 
other reasons.2 Simple, minimal data collection 
must be one of the most effective strategies for 
the prevention of missing data.
This concept is sometimes difficult to sell to 
investigators who may envision ancillary studies 
and additional publications ensuing from more 
data. However, quality trumps quantity, and per-
haps this should be made clearer in criteria for 
academic promotion.
H. Daniel Lewis, Jr., M.D.
University of Kansas School of Medicine 
Kansas City, KS 
hdanlewis@earthlink.net
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To the Editor: Little and colleagues correctly 
point out that missing data are often the result of 
study designs that mandate study discontinuation 
when treatment is discontinued.1 Intention-to-
treat inference based on randomization requires 
that patient data be collected regardless of treat-
ment status. However, an issue requires further 
clarification. When following patients who are 
off treatment, and methods are used to address 
data that are missing at random, the goal is to 
recreate a result that would have been obtained if 
patients who discontinued treatment had been 
followed after discontinuing treatment. The use 
of patients who are receiving treatment to impute 
the results for those who have discontinued treat-
ment would seem to be problematic. In addition, 
if the common practice of no longer considering 
data on patients after treatment discontinuation 
is not altered, methods to address missing data 
that are based on statistical models will have no 
similar patients from whom to model the miss-
ing data. How do the authors suggest that we 
deal with this conundrum?
Joe Hirman, Ph.D. 
Paul Flyer, Ph.D.
Pacific Northwest Statistical Consulting 
Woodinville, WA 
jhirman@pnwstat.com
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The authors reply: We agree with Lewis that 
limiting the burden on participants and investi-
gators is important in the design of a study. Ex-
cessive data collection not only creates more op-
portunities for missing data, but it can distract 
attention from the collection of critical data. 
That said, covariate data, auxiliary data, and sec-
ondary-outcome data can serve valuable purpos-
es, including improving the ability to understand 
and model the missing data.
Hirman and Flyer raise the important issue of 
the appropriate intention-to-treat analysis when 
patients go off the treatment protocol. We see 
three broad options, the relative usefulness of 
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